- Home
- DVS vs ELDN Comparison
DVS vs ELDN Comparison
Compare DVS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- ELDN
- Stock Information
- Founded
- DVS 2011
- ELDN 2004
- Country
- DVS Canada
- ELDN United States
- Employees
- DVS N/A
- ELDN N/A
- Industry
- DVS
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- ELDN Health Care
- Exchange
- DVS Nasdaq
- ELDN Nasdaq
- Market Cap
- DVS 210.3M
- ELDN 202.4M
- IPO Year
- DVS N/A
- ELDN N/A
- Fundamental
- Price
- DVS $3.46
- ELDN $2.60
- Analyst Decision
- DVS
- ELDN Strong Buy
- Analyst Count
- DVS 0
- ELDN 2
- Target Price
- DVS N/A
- ELDN $12.50
- AVG Volume (30 Days)
- DVS 311.5K
- ELDN 1.1M
- Earning Date
- DVS 08-13-2025
- ELDN 08-14-2025
- Dividend Yield
- DVS N/A
- ELDN N/A
- EPS Growth
- DVS N/A
- ELDN N/A
- EPS
- DVS N/A
- ELDN 0.21
- Revenue
- DVS N/A
- ELDN N/A
- Revenue This Year
- DVS N/A
- ELDN N/A
- Revenue Next Year
- DVS N/A
- ELDN N/A
- P/E Ratio
- DVS N/A
- ELDN $12.26
- Revenue Growth
- DVS N/A
- ELDN N/A
- 52 Week Low
- DVS $2.48
- ELDN $2.38
- 52 Week High
- DVS $4.15
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- DVS 46.51
- ELDN 37.02
- Support Level
- DVS $3.26
- ELDN $2.54
- Resistance Level
- DVS $3.73
- ELDN $2.71
- Average True Range (ATR)
- DVS 0.14
- ELDN 0.16
- MACD
- DVS -0.02
- ELDN -0.03
- Stochastic Oscillator
- DVS 42.55
- ELDN 17.27
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.